CellRapeutics™ Anti-SARS-CoV-2 CAR Cell Therapy Development

Online Inquiry

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The development of anti-SARS-CoV-2 CAR cell therapy holds significant potential in the fight against COVID-19, offering versatile approaches to both treatment and prevention strategies. Creative Biolabs provides valuable support in the development of cell therapies to combat SARS-CoV-2 by providing comprehensive services that cover all phases of CAR cell therapy development.

Background

Despite the availability of vaccines and antiviral drugs, there remains a need for alternative therapeutic approaches for COVID-19, particularly for individuals who are unresponsive to existing treatments or those with severe disease. CAR cell therapy offers a novel and potentially potent strategy for targeting SARS-CoV-2-infected cells and modulating the immune response. CAR-T cells can be engineered to recognize specific viral antigens with high affinity and specificity, allowing for precise targeting of infected cells while minimizing off-target effects. By redirecting the immune system to attack SARS-CoV-2-infected cells, CAR cell therapy can potentially achieve potent and durable antiviral responses.

Fig.1 Schematic diagram. (Chen, Zhenzhong et al., 2022) Fig.1 CAR-T cells that recognize the SARS-CoV-2 virus.¹

Anti-SARS-CoV-2 CAR Cell Therapy Development at Creative Biolabs

Based on scientific expertise, advanced technology, Creative Biolabs offers a full-service approach covering all aspects of SARS-CoV-2 CAR cell therapy development:

Biomarker Identification & Selection

Identify specific antigens or epitopes on the surface of SARS-CoV-2-infected cells that can serve as targets for CAR-T cell recognition.

SARS-CoV-2 CAR Design

Design a CAR construct that consists of an antigen-binding domain, a transmembrane domain, co-stimulatory domains, and signaling domains.

SARS-CoV-2 CAR-T Gene Packaging & Delivery

Genetically modify patient-derived T cells to express the CAR construct using viral vectors like lentivirus or retrovirus.

SARS-CoV-2 CAR In Vitro Testing

Evaluate the functionality and specificity of engineered CAR-T cells in vitro using assays like cytokine release assays, cytotoxicity assays, and co-culture experiments with SARS-CoV-2-infected cells.

Preclinical In Vivo Studies

Conduct preclinical studies in animal models to assess the safety, efficacy, and pharmacokinetics of CAR-T cell therapy.

For more information on CAR-T therapy development, you can click here to jump to the corresponding page for more information!

Display Results

The following results are derived from the latest research advances in SARS-CoV-2 CAR therapeutics, and illustrate the construction of SARS-CoV-2 CARs and the expression levels of SARS-CoV-2 CARs. Hopefully, these results will help you better understand our anti-SARS-CoV-2 CAR cell therapy development services.

Engineering SARS-CoV-2 CAR
Fig.2 Diagram of SARS-CoV-2 infected cells and spike protein expression plasmids.²	Fig.2 a tested the relationship between the SARS-CoV-2 spike protein on the cell surface and T cells. Fig.2 b is a schematic diagram of the CAR molecule that recognizes the spike protein on the cell surface.
Fig.3 Flow cytometry for transfection and lentiviral transduction.²	Fig.3 c shows Spike expression on the cell surface after transfection. Fig.3 d shows the expression of Spike and GFP in engineered 293 cells.
Fig.4 Diagram of anti-SARS-CoV-2 Spike protein CAR constructs.²	The left figure shows a schematic diagram of the structure of a slow-moving construct containing either an ACE2 CAR or an anti-spike CAR cassette.

Expression of CAR constructs
Fig.5 Expression of CAR constructs on CD8 T cells.²	The left figure shows the surface expression of ACE2 and anti-spike on CAR-engineered CD8 T cells.

Applications of Anti-SARS-CoV-2 CAR Cell Therapy Development

Anti-SARS-CoV-2 CAR cell therapy development holds promise in various applications aimed at combating COVID-19 and its associated complications. Here are several potential applications:

Through comprehensive CAR T-cell therapy services, Creative Biolabs is advancing the development of anti-SARS-CoV-2 CAR cell therapies, potentially providing powerful new tools for global efforts to control the COVID-19 pandemic. If you have a need in the field of SARS-CoV-2 CAR, please feel free to contact us.

References

Wang, Yiyuan et al. "Immune-cell-based therapy for COVID-19: current status" Viruses. (2023) 15, no. 11: 2148.
Dogan, Mikail et al. "Targeting SARS-CoV-2 infection through CAR-T-like bispecific T cell engagers incorporating ACE2." Clinical & translational immunology. (2022) 11,10 e1421.